Moreover, since elevated levels IL-6 occurring in patients with RA can reduce CYP activity, thus increasing drug levels compared to subjects without RA, the blockade of IL-6 signaling can reverse the inhibitory effect of IL-6 and restore CYP activity, leading to altered drug concentrations. The gene discussed is PPIG; the disease is rheumatoid arthritis.